Regeneron melanoma drug trial fails to meet primary endpoint

May 15, 2026 8:19 PM

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported that its Phase 3 trial evaluating fianlimab, a LAG-3 inhibitor, in combination with cemiplimab ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found